Trimodulin: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -17% 1 166 Improvement, Studies, Patients Relative Risk Mortality -17% 1 166 Ventilation -9% 1 166 RCTs -17% 1 166 Late -17% 1 166 Trimodulin for COVID-19 c19early.org December 2025 Favorstrimodulin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -17% 1.17 [0.63-2.16] death 18/84 15/82 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Late treatment -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk All studies -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk 1 trimodulin COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Effect extraction pre-specified(most serious outcome) Favors trimodulin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -17% 1.17 [0.63-2.16] 18/84 15/82 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Late treatment -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk All studies -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk 1 trimodulin COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Favors trimodulin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -9% 1.09 [0.79-1.49] 84 (n) 82 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -9% 1.09 [0.79-1.49] 84 (n) 82 (n) 9% higher risk All studies -9% 1.09 [0.79-1.49] 84 (n) 82 (n) 9% higher risk 1 trimodulin COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Favors trimodulin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -17% 1.17 [0.63-2.16] death 18/84 15/82 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Late treatment -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk All studies -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk 1 trimodulin COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Effect extraction pre-specified(most serious outcome) Favors trimodulin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -17% 1.17 [0.63-2.16] 18/84 15/82 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Late treatment -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk All studies -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk 1 trimodulin COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Favors trimodulin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -17% 1.17 [0.63-2.16] death 18/84 15/82 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Late treatment -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk All studies -17% 1.17 [0.63-2.16] 18/84 15/82 17% higher risk 1 trimodulin COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.63 Effect extraction pre-specified(most serious outcome) Favors trimodulin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ESsCOVID Agafina (DB RCT) -17% 1.17 [0.63-2.16] death 18/84 15/82 Improvement, RR [CI] Treatment Control ESsCOVID Agafina (DB RCT) 2% 0.98 [0.64-1.50] progression 28/84 28/82 ESsCOVID Agafina (DB RCT) -9% 1.09 [0.79-1.49] ventilation time 84 (n) 82 (n) Trimodulin COVID-19 outcomes c19early.org December 2025 Favors trimodulin Favors control